AcuCort has postponed the publication of its third-quarter interim report to November 29, 2024. The report was initially scheduled for release on November 22.
AcuCort previously announced that the company would present the results of the study “Swedish Allergists’ View on the Role of Cortisone and the Formulation (Tablets or Self-Dissolving Film) for the Treatment of Acute Allergic Reactions” at the ISPOR scientific conference in Barcelona.
Due to the high level of interest in the study’s results, AcuCort’s CEO, Jonas Jönmark, will attend the conference in Barcelona from November 17–20. Consequently, AcuCort’s Q3 interim report and its accompanying commentary are rescheduled to November 29, 2024.
For further information:
Jonas Jönmark, vd, AcuCort AB
Telefon: 070 365 5400
Epost: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.
